Transcranial magnetic stimulation explained

Transcranial magnetic stimulation

Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to induce an electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil connected to the scalp. The stimulator generates a changing electric current within the coil which creates a varying magnetic field, inducing a current within a region in the brain itself.[1] [2]

TMS has shown diagnostic and therapeutic potential in the central nervous system with a wide variety of disease states in neurology and mental health, but has no demonstrated clinical worth for treatment of any condition.

Adverse effects of TMS appear rare and include fainting and seizure.[3] Other potential issues include discomfort, pain, hypomania, cognitive change, hearing loss, and inadvertent current induction in implanted devices such as pacemakers or defibrillators.

Medical uses

TMS does not require surgery or electrode implantation.

Its use can be diagnostic and/or therapeutic. Effects vary based on frequency and intensity of the magnetic pulses as well as the length of treatment, which dictates the total number of pulses given.[4] TMS treatments are approved by the FDA in the US and by NICE in the UK for the treatment of depression and are predominantly provided by private clinics. TMS stimulates cortical tissue without the pain sensations produced in transcranial electrical stimulation.[5]

Diagnosis

TMS can be used clinically to measure activity and function of specific brain circuits in humans, most commonly with single or paired magnetic pulses.[6] The most widely accepted use is in measuring the connection between the primary motor cortex of the central nervous system and the peripheral nervous system to evaluate damage related to past or progressive neurologic insult.[7] [8] [9] TMS has utility as a diagnostic instrument for myelopathy, amyotrophic lateral sclerosis, and multiple sclerosis.[10]

Treatment

There is some evidence that TMS may have applications for a number of conditions including depression, fibromyalgia and neuropathic pain, but for no condition does the evidence rise to the level of showing clinical relevance.[11]

Adverse effects

Although TMS is generally regarded as safe, risks are increased for therapeutic rTMS compared to single or paired diagnostic TMS.[12] Adverse effects generally increase with higher frequency stimulation.

The greatest immediate risk from TMS is fainting, though this is uncommon. Seizures have been reported, but are rare.[13] [14] Other adverse effects include short term discomfort, pain, brief episodes of hypomania, cognitive change, hearing loss, impaired working memory, and the induction of electrical currents in implanted devices such as cardiac pacemakers.

Procedure

During the procedure, a magnetic coil is positioned at the head of the person receiving the treatment using anatomical landmarks on the skull, in particular the inion and nasion.[15] The coil is then connected to a pulse generator, or stimulator, that delivers electric current to the coil.

Physics

See main article: article and Electromagnetic induction. TMS uses electromagnetic induction to generate an electric current across the scalp and skull.[16] [17] A plastic-enclosed coil of wire is held next to the skull and when activated, produces a varying magnetic field oriented orthogonally to the plane of the coil. The changing magnetic field then induces an electric current in the brain that activates nearby nerve cells in a manner similar to a current applied superficially at the cortical surface.[18]

The magnetic field is about the same strength as magnetic resonance imaging (MRI), and the pulse generally reaches no more than 5 centimeters into the brain unless using a modified coil and technique for deeper stimulation.[17]

Transcranial magnetic stimulation is achieved by quickly discharging current from a large capacitor into a coil to produce pulsed magnetic fields between 2 and 3 teslas in strength.[19] Directing the magnetic field pulse at a targeted area in the brain causes a localized electrical current which can then either depolarize or hyperpolarize neurons at that site. The induced electric field inside the brain tissue causes a change in transmembrane potentials resulting in depolarization or hyperpolarization of neurons, causing them to be more or less excitable, respectively.

TMS usually stimulates to a depth from 2 to 4 cm below the surface, depending on the coil and intensity used. Consequently, only superficial brain areas can be affected.[20] Deep TMS can reach up to 6 cm into the brain to stimulate deeper layers of the motor cortex, such as that which controls leg motion. The path of this current can be difficult to model because the brain is irregularly shaped with variable internal density and water content, leading to a nonuniform magnetic field strength and conduction throughout its tissues.[21]

Frequency and duration

The effects of TMS can be divided based on frequency, duration and intensity (amplitude) of stimulation:[22]

Coil types

Most devices use a coil shaped like a figure-eight to deliver a shallow magnetic field that affects more superficial neurons in the brain.[27] Differences in magnetic coil design are considered when comparing results, with important elements including the type of material, geometry and specific characteristics of the associated magnetic pulse.

The core material may be either a magnetically inert substrate ('air core'), or a solid, ferromagnetically active material ('solid core'). Solid cores result in more efficient transfer of electrical energy to a magnetic field and reduce energy loss to heat, and so can be operated with the higher volume of therapy protocols without interruption due to overheating. Varying the geometric shape of the coil itself can cause variations in focality, shape, and depth of penetration. Differences in coil material and its power supply also affect magnetic pulse width and duration.[28]

A number of different types of coils exist, each of which produce different magnetic fields. The round coil is the original used in TMS. Later, the figure-eight (butterfly) coil was developed to provide a more focal pattern of activation in the brain, and the four-leaf coil for focal stimulation of peripheral nerves. The double-cone coil conforms more to the shape of the head.[29] The Hesed (H-core), circular crown and double cone coils allow more widespread activation and a deeper magnetic penetration. They are supposed to impact deeper areas in the motor cortex and cerebellum controlling the legs and pelvic floor, for example, though the increased depth comes at the cost of a less focused magnetic pulse.

Research directions

For Parkinson's disease, early results suggest that low frequency stimulation may have an effect on medication associated dyskinesia, and that high frequency stimulation improves motor function.[30] [31]

History

Luigi Galvani (1737–1798) undertook research on the effects of electricity on the body in the late-eighteenth century and laid the foundations for the field of electrophysiology.[32] In the 1830s Michael Faraday (1791–1867) discovered that an electrical current had a corresponding magnetic field, and that changing one could induce its counterpart.[33]

Work to directly stimulate the human brain with electricity started in the late 1800s, and by the 1930s the Italian physicians Cerletti and Bini had developed electroconvulsive therapy (ECT).[32] ECT became widely used to treat mental illness, and ultimately overused, as it began to be seen as a panacea. This led to a backlash in the 1970s.[32]

In 1980 Merton and Morton successfully used transcranial electrical stimulation (TES) to stimulate the motor cortex. However, this process was very uncomfortable, and subsequently Anthony T. Barker began to search for an alternative to TES.[34] He began exploring the use of magnetic fields to alter electrical signaling within the brain, and the first stable TMS devices were developed in 1985.[32] [33] They were originally intended as diagnostic and research devices, with evaluation of their therapeutic potential being a later development.[32] [33] The United States' FDA first approved TMS devices in October 2008.[32]

Regulatory status

Speech mapping prior to neurosurgery

Nexstim obtained United States Federal Food, Drug, and Cosmetic Act§Section 510(k) clearance for the assessment of the primary motor cortex for pre-procedural planning in December 2009[35] and for neurosurgical planning in June 2011.[36]

Depression

TMS is approved as a Class II medical device under the "de novo pathway".[37] [38]

Obsessive–compulsive disorder (OCD)

In August 2018, the US Food and Drug Administration (US FDA) authorized the use of TMS developed by the Israeli company Brainsway in the treatment of obsessive–compulsive disorder (OCD).[39]

In 2020, US FDA authorized the use of TMS developed by the U.S. company MagVenture Inc. in the treatment of OCD.[40]

In 2023, US FDA authorized the use of TMS developed by the U.S. company Neuronetics Inc. in the treatment of OCD.[41]

Other neurological areas

In the European Economic Area, various versions of deep TMS H-coils have CE marking forAlzheimer's disease,autism,bipolar disorder,epilepsy,[42] chronic pain,major depressive disorder,Parkinson's disease,[43] [44] post-traumatic stress disorder (PTSD),[45] schizophrenia (negative symptoms)[46] and to aid smoking cessation.[47] One review found tentative benefit for cognitive enhancement in healthy people.[48]

Coverage by health services and insurers

United Kingdom

The United Kingdom's National Institute for Health and Care Excellence (NICE) issues guidance to the National Health Service (NHS) in England, Wales, Scotland and Northern Ireland (UK). NICE guidance does not cover whether or not the NHS should fund a procedure. Local NHS bodies (primary care trusts and hospital trusts) make decisions about funding after considering the clinical effectiveness of the procedure and whether the procedure represents value for money for the NHS.[49]

NICE evaluated TMS for severe depression (IPG 242) in 2007, and subsequently considered TMS for reassessment in January 2011 but did not change its evaluation.[50] The Institute found that TMS is safe, but there is insufficient evidence for its efficacy.

In January 2014, NICE reported the results of an evaluation of TMS for treating and preventing migraine (IPG 477). NICE found that short-term TMS is safe but there is insufficient evidence to evaluate safety for long-term and frequent uses. It found that evidence on the efficacy of TMS for the treatment of migraine is limited in quantity, that evidence for the prevention of migraine is limited in both quality and quantity.[51]

Subsequently, in 2015, NICE approved the use of TMS for the treatment of depression in the UK and IPG542 replaced IPG242.[52] NICE said "The evidence on repetitive transcranial magnetic stimulation for depression shows no major safety concerns. The evidence on its efficacy in the short-term is adequate, although the clinical response is variable. Repetitive transcranial magnetic stimulation for depression may be used with normal arrangements for clinical governance and audit."

United States: commercial health insurance

In 2013, several commercial health insurance plans in the United States, including Anthem, Health Net, and Blue Cross Blue Shield of Nebraska and of Rhode Island, covered TMS for the treatment of depression for the first time.[53] [54] [55] [56] In contrast, UnitedHealthcare issued a medical policy for TMS in 2013 that stated there is insufficient evidence that the procedure is beneficial for health outcomes in patients with depression. UnitedHealthcare noted that methodological concerns raised about the scientific evidence studying TMS for depression include small sample size, lack of a validated sham comparison in randomized controlled studies, and variable uses of outcome measures.[57] Other commercial insurance plans whose 2013 medical coverage policies stated that the role of TMS in the treatment of depression and other disorders had not been clearly established or remained investigational included Aetna, Cigna and Regence.[58] [59] [60]

United States: Medicare

Policies for Medicare coverage vary among local jurisdictions within the Medicare system,[61] and Medicare coverage for TMS has varied among jurisdictions and with time. For example:

Limitations

There are serious concerns about stimulating brain tissue using non-invasive magnetic field methods:

First, the uncertainty in the dose (time and technical field parameters) for correct and healthy stimulation is a complex and challenging issue.[69] While neurophysiology lacks knowledge about the nature of such a treatment of nervous diseases at the cellular level,[70] this method involves excessive exposure of the brain to an intense field, which is several times and even orders of magnitude higher than natural electromagnetic fields in the brain.[71] [72]

Second, it is impossible to localize the effect of stimulation on specific neural networks that need to be treated.[73] Neuronal activity related to mental processes, neuronal correlates of cognitive functions are still intriguing questions for contemporary research. Non-invasive brain tissue stimulation targets a large area of poorly characterized tissue. An undefined dose and target of radiation can destroy healthy cells during a treatment procedure. Because it is unclear whether magnetic fields reach only those neural structures of the brain that need treatment, this uncertainty challenges the selection of treatment for neurological disorders by magnetic fields. Thus, magnetic field exposure may destroy healthy neuronal structures. The inability to localize the effect of stimulation makes it challenging to target stimulation only to the desired neural networks.

See also

Notes and References

  1. NICE. January 2014 Transcranial magnetic stimulation for treating and preventing migraine
  2. Michael Craig Miller for Harvard Health Publications. July 26, 2012 Magnetic stimulation: a new approach to treating depression?
  3. Rossi . et al. . Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. . Clinical Neurophysiology . January 2021 . 132 . 1 . 269–306 . 10.1016/j.clinph.2020.10.003 . 33243615 . 9094636 . 225049093 .
  4. 2015-09-01. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Annals of Physical and Rehabilitation Medicine. en. 58. 4. 208–213. 10.1016/j.rehab.2015.05.005. 1877-0657. free. Klomjai. Wanalee. Katz. Rose. Lackmy-Vallée. Alexandra. 26319963.
  5. Book: Lefaucher . Jean-Pascal . Handbook of Clinical Neurology . 2019 . Elsevier . 9780444640321 . 559–580 . 29 March 2024 . 37 .
  6. Groppa S, Oliviero A, Eisen A, Quartarone A, Cohen LG, Mall V, Kaelin-Lang A, Mima T, Rossi S, Thickbroom GW, Rossini PM, Ziemann U, Valls-Solé J, Siebner HR . 6 . A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee . Clinical Neurophysiology . 123 . 5 . 858–882 . May 2012 . 22349304 . 4890546 . 10.1016/j.clinph.2012.01.010 .
  7. Rossini PM, Rossi S . Transcranial magnetic stimulation: diagnostic, therapeutic, and research potential . Neurology . 68 . 7 . 484–488 . February 2007 . 17296913 . 10.1212/01.wnl.0000250268.13789.b2 . 19629888 .
  8. Dimyan MA, Cohen LG . Contribution of transcranial magnetic stimulation to the understanding of functional recovery mechanisms after stroke . Neurorehabilitation and Neural Repair . 24 . 2 . 125–135 . February 2010 . 19767591 . 2945387 . 10.1177/1545968309345270 .
  9. Nowak DA, Bösl K, Podubeckà J, Carey JR . Noninvasive brain stimulation and motor recovery after stroke . Restorative Neurology and Neuroscience . 28 . 4 . 531–544 . 2010 . 20714076 . 10.3233/RNN-2010-0552 .
  10. Chen . Robert . Cros . Didier . Curra . Antonio . Di Lazzaro . Vincenzo . Lefaucheur . Jean-Pascal . Magistris . Michel R. . Mills . Kerry . Rösler . Kai M. . Triggs . William J. . Ugawa . Yoshikazu . Ziemann . Ulf . The clinical diagnostic utility of transcranial magnetic stimulation: Report of an IFCN committee . Clinical Neurophysiology . March 2008 . 119 . 3 . 504–532 . 10.1016/j.clinph.2007.10.014.
  11. Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipović SR, Grefkes C, Hasan A, Hummel FC, Jääskeläinen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorová I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U . Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018) . Clin Neurophysiol . 131 . 2 . 474–528 . February 2020 . 31901449 . 10.1016/j.clinph.2019.11.002 . 5 . The present work only provides arguments to be confident that some rTMS protocols do something that is different from a placebo in some indications, but not that the results obtained are clinically relevant. 10362/147799 . free .
  12. van den Noort M, Lim S, Bosch P . Recognizing the risks of brain stimulation . Science . 346 . 6215 . 1307 . December 2014 . 25504707 . 10.1126/science.346.6215.1307-a . 2066/133976 . free .
  13. Dobek CE, Blumberger DM, Downar J, Daskalakis ZJ, Vila-Rodriguez F . Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion . Neuropsychiatric Disease and Treatment . 11 . 2975–2987 . 2015 . 26664122 . 4670017 . 10.2147/NDT.S91126 . free .
  14. Book: Fitzgerald PB, Daskalakis ZJ . https://books.google.com/books?id=2VFEAAAAQBAJ. Repetitive Transcranial Magnetic Stimulation for Depressive Disorders. 7. rTMS-Associated Adverse Events. 81–90. Berlin Heidelberg. Springer-Verlag. 2013. 10.1007/978-3-642-36467-9. 978-3-642-36466-2.
  15. Nauczyciel C, Hellier P, Morandi X, Blestel S, Drapier D, Ferre JC, Barillot C, Millet B . 6 . Assessment of standard coil positioning in transcranial magnetic stimulation in depression . Psychiatry Research . 186 . 2–3 . 232–238 . April 2011 . 20692709 . 10.1016/j.psychres.2010.06.012 . 25100990 .
  16. Cavaleri R, Schabrun SM, Chipchase LS . The number of stimuli required to reliably assess corticomotor excitability and primary motor cortical representations using transcranial magnetic stimulation (TMS): a systematic review and meta-analysis . Systematic Reviews . 6 . 1 . 48 . March 2017 . 28264713 . 5340029 . 10.1186/s13643-017-0440-8 . free .
  17. Web site: Brain Stimulation Therapies . NIMH .
  18. Book: Handbook of psychophysiology . 2007 . Cambridge Univ. Press . New York . 978-0-521-84471-0 . 3rd . Cacioppo JT, Tassinary LG, Berntson GG . 121.
  19. V. Walsh and A. Pascual-Leone, "Transcranial Magnetic Stimulation: A Neurochronometrics of Mind." Cambridge, Massachusetts: MIT Press, 2003.
  20. Lefaucheur . Jean-Pascal . André-Obadia . Nathalie . Antal . Andrea . Ayache . Samar S. . Baeken . Chris . Benninger . David H. . Cantello . Roberto M. . Cincotta . Massimo . de Carvalho . Mamede . De Ridder . Dirk . Devanne . Hervé . Di Lazzaro . Vincenzo . Filipović . Saša R. . Hummel . Friedhelm C. . Jääskeläinen . Satu K. . November 2014 . Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) . Clinical Neurophysiology . en . 125 . 11 . 2150–2206 . 10.1016/j.clinph.2014.05.021.
  21. See:
    1. Zangen A, Roth Y, Voller B, Hallett M . Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil . Clinical Neurophysiology . 116 . 4 . 775–779 . April 2005 . 15792886 . 10.1016/j.clinph.2004.11.008 . 25101101 .
    2. Huang YZ, Sommer M, Thickbroom G, Hamada M, Pascual-Leonne A, Paulus W, Classen J, Peterchev AV, Zangen A, Ugawa Y . 6 . Consensus: New methodologies for brain stimulation . Brain Stimulation . 2 . 1 . 2–13 . January 2009 . 20633398 . 5507351 . 10.1016/j.brs.2008.09.007 .
  22. Rubens MT, Zanto TP . Parameterization of transcranial magnetic stimulation . Journal of Neurophysiology . 107 . 5 . 1257–1259 . March 2012 . 22072509 . 3311692 . 10.1152/jn.00716.2011 .
  23. Book: Alvaro Pascual-Leone . Pascual-Leone A, Davey N, Rothwell J, Wassermann EM, Puri BK . 2002 . Handbook of Transcranial Magnetic Stimulation . Edward Arnold. London . 978-0-340-72009-7 .
  24. Cusin C, Dougherty DD . Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS . Biology of Mood & Anxiety Disorders . 2 . 1 . 14 . August 2012 . 22901565 . 3514332 . 10.1186/2045-5380-2-14 . free .
  25. Fitzgerald PB, Fountain S, Daskalakis ZJ . A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition . Clinical Neurophysiology . 117 . 12 . 2584–2596 . December 2006 . 16890483 . 10.1016/j.clinph.2006.06.712 . 31458874 .
  26. Baur D, Galevska D, Hussain S, Cohen LG, Ziemann U, Zrenner C. Induction of LTD-like corticospinal plasticity by low-frequency rTMS depends on pre-stimulus phase of sensorimotor μ-rhythm. Brain Stimul. 2020 Nov-Dec;13(6):1580-1587. doi: 10.1016/j.brs.2020.09.005. Epub 2020 Sep 17. PMID 32949780; PMCID: PMC7710977.
  27. Bersani . F.S. . Minichino . A. . Enticott . P.G. . Mazzarini . L. . Khan . N. . Antonacci . G. . Raccah . R.N. . Salviati . M. . Delle Chiaie . R. . Bersani . G. . Fitzgerald . P.B. . Biondi . M. . Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: A comprehensive review . European Psychiatry . January 2013 . 28 . 1 . 30–39 . 10.1016/j.eurpsy.2012.02.006 . 22559998 . 29053871 .
  28. Book: Oxford Handbook of Transcranial Stimulation . Wassermann EM, Epstein CM, Ziemann U, Walsh V, Paus T, Lisanby SH . TMS Stimulator Design . Riehl M . 2008 . Oxford University Press . Oxford . 978-0-19-856892-6 . 13–23, 25–32 .
  29. Roth BJ, Maccabee PJ, Eberle LP, Amassian VE, Hallett M, Cadwell J, Anselmi GD, Tatarian GT . 6 . In vitro evaluation of a 4-leaf coil design for magnetic stimulation of peripheral nerve . Electroencephalography and Clinical Neurophysiology . 93 . 1 . 68–74 . February 1994 . 7511524 . 10.1016/0168-5597(94)90093-0 .
  30. Machado S, Bittencourt J, Minc D, Portella CE, Velasques B, Cunha M, Budde H, Basile LF, Chadi G, Cagy M, Piedade R, Riberio P . 6 . Therapeutic applications of repetitive transcranial magnetic stimulation in clinical neurorehabilitation . Functional Neurology . 23 . 3 . 113–122 . 2008 . 19152730 .
  31. Liu . Xuan . Li . Lei . Liu . Ye . 2023-09-29 . Comparative motor effectiveness of non-invasive brain stimulation techniques in patients with Parkinson's disease: A network meta-analysis . Medicine . 102 . 39 . e34960 . 10.1097/MD.0000000000034960 . 1536-5964 . 37773851. 10545289 .
  32. Horvath JC, Perez JM, Forrow L, Fregni F, Pascual-Leone A . Transcranial magnetic stimulation: a historical evaluation and future prognosis of therapeutically relevant ethical concerns . Journal of Medical Ethics . 37 . 3 . 137–143 . March 2011 . 21106996 . 10.1136/jme.2010.039966 . 23034661 . 13262044 .
  33. Noohi S, Amirsalari S . History, Studies and Specific Uses of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treating Epilepsy . Iranian Journal of Child Neurology . 10 . 1 . 1–8 . 2016 . 27057180 . 4815479 .
  34. Klomjai W, Katz R, Lackmy-Vallée A . Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS) . Annals of Physical and Rehabilitation Medicine . 58 . 4 . 208–213 . September 2015 . 26319963 . 10.1016/j.rehab.2015.05.005 . free .
  35. Web site: FDA clears Nexstim´s Navigated Brain Stimulation for non-invasive cortical mapping prior to neurosurgery – Archive – Press Releases . nexstim.com.
  36. Web site: Nexstim Announces FDA Clearance for NexSpeech® – Enabling Noninvasive Speech Mapping Prior to Neurosurgery . 11 June 2012. businesswire.com.
  37. Michael Drues, for Med Device Online. 5 February 2014 Secrets Of The De Novo Pathway, Part 1: Why Aren't More Device Makers Using It?
  38. Schwedt TJ, Vargas B . Neurostimulation for Treatment of Migraine and Cluster Headache . Pain Medicine . 16 . 9 . 1827–1834 . September 2015 . 26177612 . 4572909 . 10.1111/pme.12792 .
  39. Web site: 2020-02-20 . FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder . Food and Drug Administration.
  40. Web site: MagVenture receives FDA clearance for OCD Clinical TMS Society . 2023-10-11 . www.clinicaltmssociety.org.
  41. Web site: FDA clears OCD motor threshold cap for transcranial magnetic stimulation system . 2023-10-11 . www.healio.com . en.
  42. Gersner R, Oberman L, Sanchez MJ, Chiriboga N, Kaye HL, Pascual-Leone A, Libenson M, Roth Y, Zangen A, Rotenberg A . 6 . H-coil repetitive transcranial magnetic stimulation for treatment of temporal lobe epilepsy: A case report . Epilepsy & Behavior Case Reports . 5 . Supplement C . 52–56 . 2016-01-01 . 27114902 . 4832041 . 10.1016/j.ebcr.2016.03.001 .
  43. Chou YH, Hickey PT, Sundman M, Song AW, Chen NK . Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis . JAMA Neurology . 72 . 4 . 432–440 . April 2015 . 25686212 . 4425190 . 10.1001/jamaneurol.2014.4380 .
  44. Torres F, Villalon E, Poblete P, Moraga-Amaro R, Linsambarth S, Riquelme R, Zangen A, Stehberg J . 6 . Retrospective Evaluation of Deep Transcranial Magnetic Stimulation as Add-On Treatment for Parkinson's Disease . Frontiers in Neurology . 6 . 210 . 2015-10-26 . 26579065 . 4620693 . 10.3389/fneur.2015.00210 . free .
  45. Transcranial magnetic stimulation for post-traumatic stress disorder . 34733479 . 10.1177/20451253211049921 . free . Nicholas J. . Petrosino . Camila . Cosmo . Yosef A. . Berlow . Amin . Zandvakili . Mascha . van ’t Wout-Frank . Noah S. . Philip . . 2021 . 11 . 8558793 .
  46. Web site: Brainsway's Deep TMS EU Cleared for Neuropathic Chronic Pain. July 3, 2012 . medGadget . December 16, 2013.
  47. News: Brainsway reports positive Deep TMS system trial data for OCD. Medical Device Network. September 6, 2013 . Medicaldevice-network . December 16, 2013.
  48. Luber B, Lisanby SH . Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS) . NeuroImage . 85 Pt 3 . 3 . 961–970 . January 2014 . 23770409 . 4083569 . 10.1016/j.neuroimage.2013.06.007 .
  49. NICE About NICE: What we do
  50. Web site: Transcranial magnetic stimulation for severe depression (IPG242). London. National Institute for Health and Clinical Excellence. 2011-03-04.
  51. Web site: Transcranial magnetic stimulation for treating and preventing migraine. January 2014. London. National Institute for Health and Clinical Excellence.
  52. Web site: Repetitive transcranial magnetic stimulation for depression . 16 December 2015 . National Institute for Health and Care Excellence . 6 December 2019.
  53. Web site: Anthem, Inc. . https://web.archive.org/web/20130729015624/http://www.anthem.com/ca/medicalpolicies/policies/mp_pw_a047769.htm. 2013-07-29. Medical Policy: Transcranial Magnetic Stimulation for Depression and Other Neuropsychiatric Disorders. Policy No. BEH.00002 . 2013-04-16. 2013-12-11. dead.
  54. Web site: Health Net. https://www.webcitation.org/6BLNdUZpk?url=https://www.healthnet.com/static/general/unprotected/pdfs/national/policies/Transcranial_Magnetic_Stimulation_Mar_12.pdf. 2012-10-11. National Medical Policy: Transcranial Magnetic Stimulation. Policy Number NMP 508. Health Net. March 2012. 2012-09-05. dead.
  55. Web site: https://web.archive.org/web/20121028032816/https://www.nebraskablue.com/~/media/pdf/Provider/Policy%20Procedure%20Manuals/MedicalPolicies.pdf. 2012-10-28. Section IV.67. Medical Policy Manual. 2011-05-18. Blue Cross Blue Shield of Nebraska. dead.
  56. Web site: https://web.archive.org/web/20130526210811/https://www.bcbsri.com/sites/default/files/polices/TranscranialMagneticStimulationasaTreatmentofDepressionandOtherPsychiatricNeurologicDisorders_0.pdf. 2013-05-26. Medical Coverage Policy: Transcranial Magnetic Stimulation for Treatment of Depression and Other Psychiatric/Neurologic Disorders. Blue Cross Blue Shield of Rhode Island. 2012-05-15. 2012-09-05. dead.
  57. Web site: UnitedHealthcare. https://web.archive.org/web/20130520172341/https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/Medical%20Policies/Medical%20Policies/Transcranial_Magnetic_Stimulation.pdf. 2013-05-20. Transcranial Magnetic Stimulation. 2013-12-01. UnitedHealthCare. 2. 2013-12-11. dead. UnitedHealthcare.
  58. Web site: Aetna. https://web.archive.org/web/20131022055505/http://www.aetna.com/cpb/medical/data/400_499/0469.html. 2013-10-22. Clinical Policy Bulletin: Transcranial Magnetic Stimulation and Cranial Electrical Stimulation. 2013-10-11. Number 0469. Aetna. 2013-12-11. dead. Aetna.
  59. Web site: Cigna. https://web.archive.org/web/20170204194830/https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm_0383_coveragepositioncriteria_transcranial_magnetic_stimulation.pdf. 2017-02-04. Cigna Medical Coverage Policy: Transcranial Magnetic Stimulation. 2013-01-15. Coverage Policy Number 0383. Cigna. 2013-12-11. dead. Cigna.
  60. Web site: https://web.archive.org/web/20141209145816/http://blue.regence.com/trgmedpol/medicine/med148.pdf. 2014-12-09. Regence. Medical Policy: Transcranial Magnetic Stimulation as a Treatment of Depression and Other Disorders. Policy No. 17. 2013-06-01. Regence. 2013-12-11. dead. The Regence Group.
  61. Web site: Medicare Administrative Contractors. https://web.archive.org/web/20140214094931/http://cms.gov/Medicare/Medicare-Contracting/Medicare-Administrative-Contractors/MedicareAdministrativeContractors.html. 2014-02-14. Centers for Medicare and Medicaid Services. 2013-07-10. 2014-02-14. dead.
  62. Web site: NHIC, Corp.. Local Coverage Determination (LCD) for Repetitive Transcranial Magnetic Stimulation (rTMS) (L32228). https://archive.today/20140217152734/http://coverage.cms.fu.com/mcd_archive/viewlcd.asp?lcd_id=32228&lcd_version=5&basket=lcd:32228:5:Repetitive+Transcranial+Magnetic+Stimulation+(rTMS):MAC+-+Part+B:NHIC%7C%7C+Corp.+(14202):. dead. 2014-02-17. Centers for Medicare and Medicaid Services. 2013-10-24. 2014-02-17.
  63. Web site: https://web.archive.org/web/20130405070836/http://www.pbn.com/Important-Treatment-Option-for-Depression-Receives-Medicare-Coverage,66462. 2013-04-05. 2012-10-11. Important Treatment Option for Depression Receives Medicare Coverage. Press Release. 2012-03-30. PBN.com: Providence Business News. dead.
  64. Web site: The Institute for Clinical and Economic Review. June 2012. https://web.archive.org/web/20131213211022/http://cepac.icer-review.org/wp-content/uploads/2012/07/rTMS-Coverage-Policy-Analysis.pdf. 2013-12-13. Coverage Policy Analysis: Repetitive Transcranial Magnetic Stimulation (rTMS). The New England Comparative Effectiveness Public Advisory Council (CEPAC). 2013-12-11. dead.
  65. Web site: https://web.archive.org/web/20120325091400/http://www.cvmc.org/news/2012-theresa-fama-cepac. 2012-03-25. Transcranial Magnetic Stimulation Cites Influence of New England Comparative Effectiveness Public Advisory Council (CEPAC). 2012-02-06. Berlin, Vermont. Central Vermont Medical Center. 2012-10-12. dead.
  66. Web site: National Government Services, Inc. . Local Coverage Determination (LCD): Transcranial Magnetic Stimulation (L32038). 2013-10-25. . 2014-02-17.
  67. Web site: Novitas Solutions, Inc. . 2013-12-04 . LCD L32752 – Transcranial Magnetic Stimulation for Depression . 2014-02-17 . Contractor's Determination Number L32752 . Centers for Medicare and Medicaid Services.
  68. Web site: LCD L33660 – Transcranial Magnetic Stimulation (TMS) for the Treatment of Depression. Novitas Solutions, Inc.. Contractor's Determination Number L33660. Centers for Medicare and Medicaid Services. 2013-12-05. 2014-02-17.
  69. Benussi A, Pascual-Leone A, Borroni B (2020). "Non-Invasive Cerebellar Stimulation in Neurodegenerative Ataxia: A Literature Review". International Journal of Molecular Sciences. 21 (6): 1948. doi:10.3390/ijms21061948
  70. Rosa, MA; Lisanby, SH (2012). "Somatic treatments for mood disorders". Neuropsychopharmacology. 37 (1): 102–116. doi:10.1038/npp.2011.225
  71. Grimaldi G, Argyropoulos GP, Boehringer A, Celnik P, Edwards MJ, Ferrucci R, et al. (2014). "Non-invasive cerebellar stimulation--a consensus paper" (PDF). Cerebellum. 13 (1): 121–138. doi:10.1007/s12311-013-0514-7
  72. Siebner HR, Hartwigsen G, Kassuba T, Rothwell JC (2009). "How does transcranial magnetic stimulation modify neuronal activity in the brain? Implications for studies of cognition". Cortex; A Journal Devoted to the Study of the Nervous System and Behavior. 45 (9): 1035–1042. doi:10.1016/j.cortex.2009.02.007
  73. Sparing R, Mottaghy FM (2008). "Noninvasive brain stimulation with transcranial magnetic or direct current stimulation (TMS/tDCS)-From insights into human memory to therapy of its dysfunction". Methods. 44 (4): 329–337. doi:10.1016/j.ymeth.2007.02.001

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Transcranial magnetic stimulation".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.